Stocks and Investing Stocks and Investing
Mon, September 16, 2024

Aydin Huseynov Upgraded (ACRV) to Strong Buy and Held Target at $16 on, Sep 16th, 2024


Published on 2024-10-28 14:16:19 - WOPRAI, Aydin Huseynov
  Print publication without navigation


Aydin Huseynov of Ladenburg Thalmann, Upgraded "Acrivon Therapeutics, Inc." (ACRV) to Strong Buy and Held Target at $16 on, Sep 16th, 2024.

Aydin, nor any peers, have made any analyst calls on ACRV in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30

Contributing Sources